TY - JOUR T1 - The role of hyperthermia in the treatment of locally advanced cervical cancer: a comprehensive review JF - International Journal of Gynecologic Cancer JO - Int J Gynecol Cancer SP - 288 LP - 296 DO - 10.1136/ijgc-2021-002473 VL - 32 IS - 3 AU - Marloes IJff AU - Johannes Crezee AU - Arlene L Oei AU - Lukas J A Stalpers AU - Henrike Westerveld Y1 - 2022/03/01 UR - http://ijgc.bmj.com/content/32/3/288.abstract N2 - Radiotherapy with cisplatin (chemoradiation) is the standard treatment for women with locally advanced cervical cancer. Radiotherapy with deep hyperthermia (thermoradiation) is a well established alternative, but is rarely offered as an alternative to chemoradiation, particularly for patients in whom cisplatin is contraindicated. The scope of this review is to provide an overview of the biological rationale of hyperthermia treatment delivery, including patient workflow, and the clinical effectiveness of hyperthermia as a radiosensitizer in the treatment of cervical cancer. Hyperthermia is especially effective in hypoxic and nutrient deprived areas of the tumor where radiotherapy is less effective. Its radiosensitizing effectiveness depends on the temperature level, duration of treatment, and the time interval between radiotherapy and hyperthermia. High quality hyperthermia treatment requires an experienced team, adequate online adaptive treatment planning, and is preferably performed using a phased array radiative locoregional hyperthermia device to achieve the optimal thermal dose effect. Hyperthermia is well tolerated and generally leads to only mild toxicity, such as patient discomfort. Patients in whom cisplatin is contraindicated should therefore be referred to a hyperthermia center for thermoradiation. ER -